ESR2 and cancer: In contrast to the limited data on ERβ5 a large number of publications have suggested that ERβ1, the full-length ESR2 isoform, which has an intact ligand-binding pocket, acts as a negative modulator of ERα in breast and other cancer cells (Chang et al. 2006, Zhaoet al. 2007).